Published in:
01-10-2017 | Original Article
Single-Center Experience Using Selexipag in a Pediatric Population
Authors:
Roberto Gallotti, Diana E. Drogalis-Kim, Gary Satou, Juan Alejos
Published in:
Pediatric Cardiology
|
Issue 7/2017
Login to get access
Abstract
Pulmonary arterial hypertension (PAH) is a rare and progressive disorder. Current treatment in the pediatric population includes phosphodiesterase 5 inhibitors (PDE-5i), endothelin receptor antagonists (ERA), and both inhaled and intravenous prostacyclin pathway agonists. As of December 22, 2015 the first oral prostacyclin pathway agonist, selexipag (Uptravi®), was FDA approved in the US. In this case series, we discuss our single-center experience using selexipag in a pediatric population, composed of both patients with idiopathic PAH, and patients with congenital heart disease and PAH.